HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zero-Flow Pressure Measured Immediately After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Provides the Best Invasive Index for Predicting the Extent of Myocardial Infarction at 6 Months: An OxAMI Study (Oxford Acute Myocardial Infarction).

AbstractOBJECTIVES:
The aim of this study was to define which measure of microvascular best predicts the extent of left ventricular (LV) infarction.
BACKGROUND:
Microvascular injury after ST-segment elevation myocardial infarction (STEMI) is an important determinant of outcome. Several invasive measures of the microcirculation at primary percutaneous coronary intervention (PPCI) have been described. One such measure is zero-flow pressure (Pzf), the calculated pressure at which coronary flow would cease.
METHODS:
In 34 STEMI patients, Pzf, hyperemic microvascular resistance (hMR), and index of microcirculatory resistance (IMR) were derived using thermodilution flow/pressure and Doppler flow/pressure wire assessment of the infarct-related artery following PPCI. The extent of infarction was determined by blinded late gadolinium enhancement on cardiac magnetic resonance at 6 months post-PPCI. Infarction of ≥24% total LV mass was used as a categorical cutoff in receiver-operating characteristic curve analysis.
RESULTS:
Pzf was superior to both hMR and IMR for predicting ≥24% infarction area under the curve: 0.94 for Pzf versus 0.74 for hMR (p = 0.04) and 0.54 for IMR (p = 0.003). Pzf ≥42 mm Hg was the optimal cutoff value, offering 100% sensitivity and 73% specificity. Patients with Pzf ≥42 mm Hg also had a lower salvage index (61.3 ± 8.1 vs. 44.4 ± 16.8, p = 0.006) and 6-month ejection fraction (62.4 ± 3.6 vs. 49.9 ± 9.6, p = 0.002). In addition, there were significant direct relationships between Pzf and troponin area under the curve (rho = 0.55, p = 0.002), final infarct mass (rho = 0.75, p < 0.0001), percentage of LV infarction and percent transmurality of infarction (rho = 0.77 and 0.74, respectively, p < 0.0001), and inverse relationships with myocardial salvage index (rho = -0.53, p = 0.01) and 6-month ejection fraction (rho = -0.73, p = 0.0001).
CONCLUSIONS:
Pzf measured at the time of PPCI is a better predictor of the extent of myocardial infarction than hMR or IMR. Pzf may provide important prognostic information at the time of PPCI and merits further investigation in clinical studies with relevant outcome measures.
AuthorsNiket Patel, Ricardo Petraco, Erica Dall'Armellina, George Kassimis, Giovanni Luigi De Maria, Sam Dawkins, Regent Lee, Bernard D Prendergast, Robin P Choudhury, John C Forfar, Keith M Channon, Justin Davies, Adrian P Banning, Rajesh K Kharbanda
JournalJACC. Cardiovascular interventions (JACC Cardiovasc Interv) Vol. 8 Issue 11 Pg. 1410-1421 (Sep 2015) ISSN: 1876-7605 [Electronic] United States
PMID26404192 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Contrast Media
Topics
  • Aged
  • Area Under Curve
  • Cardiac Catheterization
  • Contrast Media
  • Coronary Angiography
  • Coronary Circulation
  • Coronary Vessels (physiopathology)
  • Echocardiography, Doppler
  • England
  • Female
  • Humans
  • Magnetic Resonance Imaging, Cine
  • Male
  • Microcirculation
  • Middle Aged
  • Myocardial Infarction (diagnosis, physiopathology, therapy)
  • Myocardium (pathology)
  • Percutaneous Coronary Intervention (adverse effects)
  • Predictive Value of Tests
  • ROC Curve
  • Risk Assessment
  • Risk Factors
  • Thermodilution
  • Time Factors
  • Treatment Outcome
  • Vascular Resistance
  • Ventricular Function, Left

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: